FITC-Dextran is a novel and potent marker consisting of coupling fluorescein-isothiocyanate to dextran. They are polysaccharides composed of varying lengths of branched glucose molecules with molecular weights ranging from 4-70 kDa. FITC-Dextran can be used to determine solute, ion and protein permeability of the blood-brain barrier (BBB) based on the size of the dextran used.

Exifone is a novel and potent bioactive compound

Piretanide (Eurelix; Tauliz; Arelix) is a novel and potent loop diuretic acting as a time- and voltage-dependent blocker of CFTR Cl(-) currents. It has potential to be used for hypertension and CHF/congestive heart failure with a potential advantage of having potassium-sparing properties.

Nifenalol, formerly known as INPEA, is a new beta-adrenergic receptor antagonist.

AKT-I-1 is a selective reversible inhibitor of Akt1.

Leuprorelin (A43818; NSC377526; A-43818; NSC-377526; leuprolide acetate; Leuprorelinum; Eligard) is a gonadotrophin-releasing hormone (GnRH) analogue acting as an agonist at pituitary GnRH receptors. It has been used to treat a wide range of sex hormone-related disorders such as advanced prostatic cancer, endometriosis and precocious puberty. It acts primarily on the anterior pituitary, inducing a transient […]

QS11 (QS-11) is a novel and potent inhibitor of GTPase activating protein of ADP-ribosylation factor 1 (ARF-GAP1) [EC50 of 1.5 µM] with anticancer activity.

Octenidine dihydrochloride is a topically used antiseptic, antibacterial and antimicrobial agent with activity against multidrug-resistant Gram-negative pathogens. It inhibits the expression of biofilm genes and destroys the formation of biofilms.

Recilisib sodium (formerly known as ON 01210.Na; ON-01210; ON01210; EX-RAD), the soiumd salt of recilisib, is a radioprotectant that is being studies in phase 1 clinical trials by Onconova Therapeutics for the treatment of acute radiation syndrome. It is able to mitigate radiation damage through activation of the AKT pathway. Recilisib modifies cell cycle distribution […]

Acrizanib, formerly known as LHA510, is a novel, potent and selective angiogenesis inhibitor and VEGFR‑2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration.